|
84 Companies |
|
139 Products |
|
139 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
632 News |
|
| «12345678910111213...1314» |
- || denintuzumab mafodotin (SGN-CD19A) / Pfizer
Trial primary completion date: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - May 3, 2016
P1, N=64, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Dec 2016 --> Aug 2015
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - May 3, 2016
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Aug 2015 Trial primary completion date: Apr 2016 --> Apr 2017
- Trial primary completion date: Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- || denintuzumab mafodotin (SGN-CD19A) / Pfizer
Enrollment change: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Apr 15, 2016
P1, N=64, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Dec 2015 --> Dec 2016 N=175 --> 64
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 24, 2016
P2, N=66, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
N=175 --> 64 Trial primary completion date: Mar 2016 --> Jun 2016
- Enrollment change, Trial primary completion date, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Mar 18, 2016
P1, N=44, Active, not recruiting, Sponsor: Craig Hofmeister
Trial primary completion date: Mar 2016 --> Jun 2016 N=60 --> 44 | Trial primary completion date: Dec 2015 --> Oct 2014
- || denintuzumab mafodotin (SGN-CD19A) / Seagen
Enrollment closed, Enrollment change: A Safety Study of SGN-CD19A for Leukemia and Lymphoma (clinicaltrials.gov) - Mar 7, 2016
P1, N=91, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
N=60 --> 44 | Trial primary completion date: Dec 2015 --> Oct 2014 Recruiting --> Active, not recruiting | N=175 --> 91
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells (clinicaltrials.gov) - Feb 21, 2016
P2, N=37, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | N=175 --> 91 N=20 --> 37
- | Trial completion: Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma (clinicaltrials.gov) - Feb 1, 2016
P2, N=0, Completed, Sponsor: AIDS Malignancy Consortium
N=20 --> 37 No longer recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 26, 2016
P2, N=66, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
No longer recruiting --> Completed Trial primary completion date: Dec 2015 --> Mar 2016
- OXS-1550 / GT Biopharma
Enrollment closed: DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma (clinicaltrials.gov) - Jan 25, 2016
P1, N=25, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2015 --> Mar 2016 Completed --> Active, not recruiting
- Trial initiation date, Trial primary completion date: Treg Cells for AGVHD in Non-myeloablative UCB Transplant (clinicaltrials.gov) - Jan 25, 2016
P2, N=18, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Completed --> Active, not recruiting Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: Aug 2016 --> Sep 2018
- || denintuzumab mafodotin (SGN-CD19A) / Seagen
Trial primary completion date: A Safety Study of SGN-CD19A for Leukemia and Lymphoma (clinicaltrials.gov) - Jan 21, 2016
P1, N=175, Recruiting, Sponsor: Seattle Genetics, Inc.
Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: Aug 2016 --> Sep 2018 Trial primary completion date: Dec 2015 --> Feb 2018
- Istodax (romidepsin) / Astellas, BMS, Rituxan (rituximab) / Roche
Trial initiation date: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 11, 2016
P1/2, N=56, Not yet recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2015 --> Feb 2018 Initiation date: Nov 2014 --> Jun 2016
- | Trial completion: Traumeel (clinicaltrials.gov) - Jan 5, 2016
P=N/A, N=195, Completed, Sponsor: Children's Oncology Group
Initiation date: Nov 2014 --> Jun 2016 Active, not recruiting --> Completed
- Trial primary completion date, Metastases: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=48, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Dec 2017
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 25, 2015
P2, N=20, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Dec 2017 Trial primary completion date: Jun 2014 --> Nov 2015
- cyclophosphamide / Generic mfg., thiotepa / Generic mfg.
Trial primary completion date: Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Dec 23, 2015
P2, N=25, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2014 --> Nov 2015 Trial primary completion date: Jun 2008 --> Jul 2006
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Dec 21, 2015
P2, N=14, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jun 2008 --> Jul 2006 Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015
- | cyclophosphamide / Generic mfg., thiotepa / Generic mfg.
Trial completion: Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Dec 21, 2015
P2, N=25, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Dec 6, 2015
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- || denintuzumab mafodotin (SGN-CD19A) / Pfizer
Enrollment closed: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Dec 6, 2015
P1, N=175, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- ||| denintuzumab mafodotin (SGN-CD19A) / Pfizer
Enrollment open: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Dec 4, 2015
P1, N=175, Recruiting, Sponsor: Seattle Genetics, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial termination, Trial primary completion date: Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 4, 2015
P2, N=20, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Jun 2014; Slow accrual.
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date, Post-transplantation: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Nov 26, 2015
P2, N=100, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Jun 2014; Slow accrual. Trial primary completion date: Mar 2016 --> Mar 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (clinicaltrials.gov) - Nov 26, 2015
P1/2, N=60, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Mar 2016 --> Mar 2015 Trial primary completion date: Aug 2011 --> Nov 2016
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Nov 26, 2015
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Aug 2011 --> Nov 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- || denintuzumab mafodotin (SGN-CD19A) / Pfizer
Enrollment closed, Trial primary completion date: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Oct 30, 2015
P1, N=175, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2016
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 29, 2015
P2, N=66, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2016 Trial primary completion date: Aug 2015 --> Dec 2015
- celecoxib oral / Generic mfg.
Enrollment change, Metastases: Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=0, Withdrawn, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: Aug 2015 --> Dec 2015 N=296 --> 0
- VS-4718 / Verastem
Enrollment change, Trial withdrawal: Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 22, 2015
P1, N=0, Withdrawn, Sponsor: Verastem, Inc.
N=296 --> 0 N=50 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - Oct 22, 2015
P2/3, N=640, Active, not recruiting, Sponsor: Children's Oncology Group
N=50 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 19, 2015
P2, N=50, Active, not recruiting, Sponsor: Kristie Blum
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Oct 13, 2015
P2, N=56, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=70 --> 56 | Trial primary completion date: Sep 2017 --> Oct 2015
- Trial completion: Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=434, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed | N=70 --> 56 | Trial primary completion date: Sep 2017 --> Oct 2015 Active, not recruiting --> Completed
- | leucovorin calcium / Generic mfg., cytarabine / Generic mfg.
Trial completion: Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 5, 2015
P2, N=35, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Kymriah (tisagenlecleucel-T) / Novartis
Trial initiation date: Study of Efficacy and Safety of CTL019 in Adult ALL Patients (clinicaltrials.gov) - Oct 1, 2015
P2, N=67, Not yet recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Not yet recruiting --> Completed Initiation date: Jun 2014 --> Jun 2016
- alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Enrollment change: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Sep 29, 2015
P1, N=42, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2014 --> Jun 2016 N=30 --> 42
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 26, 2015
P2, N=79, Completed, Sponsor: Kinderklinik
N=30 --> 42 Active, not recruiting --> Completed
- | ontuxizumab (MORAb-004) / Eisai
Trial completion, Enrollment change: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Sep 18, 2015
P1, N=27, Completed, Sponsor: Morphotek
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=65 --> 27
- Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Sep 16, 2015
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=65 --> 27 Trial primary completion date: Sep 2016 --> Sep 2017
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=5, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 24, 2015
P2, N=210, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014 Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015
- ||| Enrollment open, Trial primary completion date, IO biomarker: Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=150, Recruiting, Sponsor: Cancer Centre of Monoclonal Therapy, LLC
Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015 Trial primary completion date: Feb 2015 --> Jul 2015 | Active, not recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change, Metastases: Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma (clinicaltrials.gov) - Aug 20, 2015
P2, N=0, Withdrawn, Sponsor: Hoag Memorial Hospital Presbyterian
Trial primary completion date: Feb 2015 --> Jul 2015 | Active, not recruiting --> Recruiting N=80 --> 0
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Enrollment closed, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Aug 19, 2015
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=80 --> 0 Recruiting --> Active, not recruiting
- methoxyamine (TRC102) / Tracon Pharma
Trial completion: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Aug 14, 2015
P1, N=20, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial primary completion date, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Trial primary completion date: Oct 2011 --> Feb 2012
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial termination, Trial primary completion date: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Aug 13, 2015
P1, N=72, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2011 --> Feb 2012 Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jul 2015; Inadequate accrual rate
- busulfan / Generic mfg.
Trial completion, Trial primary completion date: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Aug 13, 2015
P0, N=33, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jul 2015; Inadequate accrual rate Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2015